Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clementia Pharmaceuticals Inc (NASDAQ:CMTA) and aTyr Pharma (NASDAQ:LIFE).
Clementia Pharmaceuticals Inc (CMTA)
B.Riley FBR analyst Madhu Kumar maintained a Buy rating on Clementia Pharmaceuticals Inc today and set a price target of $16. The company’s shares opened today at $8.65, close to its 52-week low of $8.10.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 27.3% and a 55.4% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Deciphera Pharmaceuticals Inc.
Clementia Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $16.
See today’s analyst top recommended stocks >>
aTyr Pharma (LIFE)
In a report released today, Matthew Luchini from BMO Capital maintained a Hold rating on aTyr Pharma, with a price target of $1. The company’s shares opened today at $0.67, close to its 52-week low of $0.61.
According to TipRanks.com, Luchini is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.0% and a 31.4% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Alder Biopharmaceuticals, and Spark Therapeutics.
aTyr Pharma has an analyst consensus of Moderate Sell, with a price target consensus of $1.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
